Antimicrobial susceptibility among gram-positive organisms collected from pediatric patients globally between 2004 and 2011: Results from the tigecycline evaluation and surveillance trial

Journal of Clinical Microbiology

Volumn 51, Issue 7, 2013, Pages 2371-2378

  Brandon, Michael ^a   Dowzicky, Michael J ^b  

^a CHILDREN S MEDICAL CENTER   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; CARBAPENEM DERIVATIVE; CEFTRIAXONE; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MEROPENEM; METICILLIN; MINOCYCLINE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

AFRICA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASIA; ASIA PCIFIC RIM; BACTERIUM ISOLATE; DRUG SURVEILLANCE PROGRAM; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; EUROPE; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; LONGITUDINAL STUDY; MIDDLE EAST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORTH AMERICA; PREVALENCE; PRIORITY JOURNAL; SOUTH AND CENTRAL AMERICA; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; TREND STUDY; ADOLESCENT; ANALOGS AND DERIVATIVES; CHILD; DRUG EFFECTS; FEMALE; GRAM POSITIVE INFECTION; HEALTH; INFANT; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; NEWBORN; PRESCHOOL CHILD;

BACTERIA (MICROORGANISMS); ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; POSIBACTERIA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; GLOBAL HEALTH; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; LONGITUDINAL STUDIES; MALE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE;

EID: 84879450580     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00157-13     Document Type: Article

References (28)

1. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T. 2009. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374:893-902.
2. Koenig JM, Keenan WJ. 2009. Group B streptococcus and early-onset sepsis in the era of maternal prophylaxis. Pediatr. Clin. North Am. 56: 689-708.
3. Thigpen MC, Whitney CG, Messonnier NE, Zell ER, Lynfield R, Hadler JL, Harrison LH, Farley MM, Reingold A, Bennett NM, Craig AS, Schaffner W, Thomas A, Lewis MM, Scallan E, Schuchat A. 2011. Bacterial meningitis in the United States, 1998-2007. N. Engl. J. Med. 364:2016-2025.
4. Willems RJL, Hanage WP, Bessen DE, Feil EJ. 2011. Population biology of Gram-positive pathogens: high-risk clones for dissemination of antibiotic resistance. FEMS Microbiol. Rev. 35:872-900.
5. Woodford N, Livermore DM. 2009. Infections caused by Gram-positive bacteria: a review of the global challenge. J. Infect. 59(Suppl 1):S4-S16. doi:10.1016/S0163-4453(09)60003-7.
6. Rice LB. 2006. Antimicrobial resistance in Gram-positive bacteria. Am. J. Med. 119(6 Suppl 1):S11-S19.
7. Teran CG, Sura S, Thant Lin TM, Medows M, Cynthia D, Wong SH. 2012. Current role of community-acquired methicillin-resistant Staphylococcus aureus among children with skin and soft tissue infections. Pediatr. Rep. 4:e5. doi:10.4081/pr.2012.e5.
8. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard, 8th ed. Document M7-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Clinical and Laboratory Standards Institute. 2010. Performance standard for antimicrobial susceptibility testing: 20th ed. Document M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Pfizer Inc (Wyeth Pharmaceuticals). 2012. Tygacil product insert. Pfizer Inc, Philadelphia, PA. http://www.pfizerpro.com/hcp/tygacil. Accessed 19 September 2012.
11. Zhanel GG, Homenuik K, Nichol K Noreddin A, Vercaigne L, Embil J, Gin A, Karlowsky JA, Hoban DJ. 2004. The glycylcyclines: a comparative review with the tetracyclines. Drugs 64:63-88.
12. Purdy J, Jouve S, Yan JL, Balter I, Dartois N, Cooper CA, Korth-Bradley J. 2012. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Clin. Ther. 34:496-507.
13. Dinleyici EC, Yargic ZA, Bor O, Kiremitci A, Durmaz G. 2010. Tigecycline treatment of multi-drug-resistant Corynebacterium jeikeium infection in a child with relapsing and refractory acute lymphoblastic leukemia. Pediatr. Blood Cancer 55:349-351.
14. Jaspan HB, Brothers AW, Campbell AJ, McGuire JK, Browd SR, Manley TJ, Pak D, Weissman SJ. 2010. Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline. Pediatr. Infect. Dis. J. 29:379-381.
15. Dowzicky MJ, Chmelar?ová E. 2011. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009. Int. J. Antimicrob. Agents 37:562-566.
16. Herigon JC, Hersh AL, Gerber JS, Zaoutis TE, Newland JG. 2010. Antibiotic management of Staphylococcus aureus infections in US children's hospitals, 1999-2008. Pediatrics 125:e1294-e1300. doi:10.1542/peds.2009-2867.
17. Johnson AP. 2011. Methicillin-resistant Staphylococcus aureus: the European landscape. J. Antimicrob. Chemother. 66(Suppl 4):iv43-iv48. doi:10.1093/jac/dkr076.
18. Tenover FC, Goering RV. 2009. Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology. J. Antimicrob. Chemother. 64:441-446.
19. Clinical and Laboratory Standards Institute. 2008. Performance standard for antimicrobial susceptibility testing: 18th informational supplement. Document M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
20. Lynch JP, III, Zhanel GG. 2010. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr. Opin. Pulm. Med. 16:217-225.
21. Högberg L, Geli P, Ringberg H, Melander E, Lipsitch M, Ekdahl K. 2007. Age-and serogroup-related differences in observed durations of nasopharyngeal carriage of penicillin-resistant pneumococci. J. Clin. Microbiol. 45:948-952.
22. Su LH, Wu TL, Kuo AJ, Chia JH, Chiu CH. 2009. Antimicrobial susceptibility of Streptococcus pneumoniae at a university hospital in Taiwan, 2000-07: impact of modified non-meningeal penicillin breakpoints in CLSI M100-S18. J. Antimicrob. Chemother. 64:336-342.
23. Crowther-Gibson P, Govender N, Lewis DA, Bamford C, Brink A, von Gottberg A, Klugman K, du Plessis M, Fali A, Harris B, Keddy K, Botha M. 2011. Situation analysis: antibiotic use and resistance in South Africa. Part IV. GARP: human infections and antibiotic resistance. S. Afr. Med. J. 101:549-596.
24. Ochoa TJ, Egoavil M, Castillo ME, Reyes I, Chaparro E, Silva W, Campos F, Sáenz A. 2010. Invasive pneumococcal diseases among hospitalized children in Lima, Peru. Rev. Panam. Salud Publica 28:121-127.
25. Garrison MW, Mutters R, Dowzicky MJ. 2009. In vitro activity of tigecycline and comparator agents against a global collection of Gramnegative and Gram-positive organisms: Tigecycline Evaluation and Surveillance Trial 2004 to 2007. Diagn. Microbiol. Infect. Dis. 65:288-299.
26. Kasahara K, Baltus AJ, Lee SH, Edelstein MA, Edelstein PH. 2010. Prevalence of non-penicillin-susceptible group B streptococcus in Philadelphia and specificity of penicillin resistance screening methods. J. Clin. Microbiol. 48:1468-1469.
27. Low DE. 2005. Changing trends in antimicrobial-resistant pneumococci: it's not all bad news. Clin. Infect. Dis. 41(Suppl 4):S228-S233.
28. Livermore DM. 1995. Beta-lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8:557-584.